Pharming Group N.V. (PHAR) Stock Score, Valuation & Financial Research
Pharming Group N.V. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 34/100.
Quick answer for PHAR
Pharming Group N.V. currently has a Wall Street Score of 34/100. The stored market price is $10.81. Its financial score is 36/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Pharming Group N.V. does
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established signi
PHAR financial snapshot
- Wall Street Score:
- 34/100
- Current price:
- $10.81
- Market capitalization:
- $764.8M
- Revenue:
- $369.5M
- Net income:
- $12.3M
- Free cash flow:
- $49.3M
- Cash:
- $53.1M
- Total debt:
- $116.2M
- EPS:
- 0.04
- P/E ratio:
- 270.1x
- Financial score:
- 36/100
- Valuation score:
- 0/100
- Revenue score:
- 26/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $49.3M, showing positive cash generation.
- The balance sheet shows $53.1M of cash versus $116.2M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 36/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research PHAR
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.